SG Americas Securities LLC Grows Position in Edwards Lifesciences Corporation $EW

SG Americas Securities LLC boosted its position in Edwards Lifesciences Corporation (NYSE:EW) by 2.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 593,482 shares of the medical research company’s stock after acquiring an additional 15,370 shares during the quarter. SG Americas Securities LLC’s holdings in Edwards Lifesciences were worth $50,594,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the company. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its holdings in shares of Edwards Lifesciences by 7.0% in the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company’s stock valued at $10,719,000 after purchasing an additional 9,069 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Edwards Lifesciences by 13.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company’s stock worth $6,706,000 after purchasing an additional 10,078 shares in the last quarter. Atlantic Union Bankshares Corp increased its holdings in Edwards Lifesciences by 2,240.9% in the third quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company’s stock valued at $925,000 after buying an additional 11,384 shares during the last quarter. Washington Trust Advisors Inc. increased its holdings in Edwards Lifesciences by 15.6% in the third quarter. Washington Trust Advisors Inc. now owns 130,587 shares of the medical research company’s stock valued at $10,156,000 after buying an additional 17,625 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp raised its stake in Edwards Lifesciences by 97.3% in the second quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock valued at $3,481,000 after buying an additional 21,950 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on EW. Robert W. Baird set a $90.00 price objective on Edwards Lifesciences in a research report on Monday, January 12th. UBS Group reissued a “neutral” rating and set a $94.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. BTIG Research restated a “buy” rating and set a $103.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, January 21st. Finally, Piper Sandler reiterated an “overweight” rating and issued a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $96.14.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $81.65 on Wednesday. The stock’s 50-day moving average is $82.16 and its two-hundred day moving average is $81.65. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. Edwards Lifesciences Corporation has a 1 year low of $65.94 and a 1 year high of $87.89. The firm has a market cap of $47.42 billion, a price-to-earnings ratio of 44.62, a PEG ratio of 2.14 and a beta of 0.93.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). The firm had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total value of $1,103,960.00. Following the completion of the sale, the chief financial officer owned 39,699 shares in the company, valued at approximately $3,371,239.08. The trade was a 24.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $85.38, for a total value of $87,002.22. Following the completion of the sale, the vice president directly owned 33,934 shares of the company’s stock, valued at $2,897,284.92. The trade was a 2.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 61,718 shares of company stock worth $5,236,281. 0.34% of the stock is owned by insiders.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.